October 30, 2025

ASCO and Google Cloud Announce AI-Powered Tool That Provides Faster, Interactive Access to ASCO’s Evidence-Based Clinical Guidelines

“Generative AI is poised to be a powerful ally for the global cancer care community.... Think of it as providing clinicians with an AI-powered assistant that never tires, always learns, and can sift t...

The ASCO Post

October 29, 2025

Single-Port Surgery for Prostate Cancer: Benefits and Challenges

A Keck Medicine of USC urologist explains why single-port surgery’s regionalization of care can yield better outcomes for prostate cancer patients.

Keck Medicine of USC

October 29, 2025

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

A U.S. Food and Drug Administration (FDA)​​-cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective eval...

The ASCO Post

October 29, 2025

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multipl...

The ASCO Post

October 29, 2025

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and MRI for breast cancer screen...

The ASCO Post

October 22, 2025

Advancing Geriatric Oncology: Where We Have Been and Where We Are Going

The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unpr...

The ASCO Post

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber

October 18, 2025

Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

Dana-Farber

October 14, 2025

Rare HeartMate 6 LVAD Saves Patient with Heart Failure After Chemotherapy

When an adverse reaction to chemotherapy sent a patient into heart failure, it took state-of-the-art treatment from an advanced cardiovascular team to save him in time.

Keck Medicine of USC